Kalydeco Coupons & Discount Card - Compare Prices Near You
My prescription
Edit
150MG, Kalydeco (30 Tablets)
Select pharmacy
Rite Aid
$14155.20
COUPON PRICE
Walgreens
$14753.47
COUPON PRICEKalydeco savings card
Show this card to your pharmacistRite Aid
$14155.20
BIN
ID
PCN
GRP
019876
LH456CDBF2
CHIPPO
LHX
Powered by
Related CFTR potentiators prescriptions
More prescriptions for cystic fibrosis
Related CFTR potentiators prescriptions
More prescriptions for cystic fibrosis
Kalydeco dosage forms
| Dosage | Quantity | Price from | Per unit |
|---|---|---|---|
| 150MG | 30 Tablets | $14336.59 | $477.89 |
Kalydeco Warnings
The following information outlines important safety precautions and potential risks associated with the use of Kalydeco (ivacaftor). Please review these details carefully and discuss any concerns with your healthcare provider.
Liver Health Monitoring: Kalydeco (ivacaftor) may cause elevated liver function tests. It is crucial to monitor liver health regularly. Your healthcare provider will perform liver tests before starting treatment, every three months during the first year, and annually thereafter. Patients with a history of liver issues may require more frequent monitoring. Seek immediate medical attention if you notice symptoms such as stomach pain, dark urine, pale stools, or yellowing of the skin or eyes.
Drug Interactions: The effectiveness and safety of Kalydeco (ivacaftor) can be influenced by interactions with other medications. It is important to inform your healthcare provider about all the medicines you are taking to manage potential interactions and side effects.
Risk of Cataracts in Children: There is a risk of cataract development in children taking Kalydeco (ivacaftor). Regular eye examinations are recommended before and during treatment. The risk may be increased if the child is also using corticosteroid medications or has been exposed to radiation.
Please ensure that you follow these guidelines and consult your healthcare provider for personalized advice and further information on managing your treatment with Kalydeco (ivacaftor).
Kalydeco Side Effects
When taking this medication, you may experience some common side effects that are usually mild and tend to resolve on their own. These include headaches, sore throat, upper respiratory tract infections like coughs and colds, stuffy nose, stomach pain, common colds, diarrhea, rashes, nausea, and dizziness. It's important to note that while these effects are common, they are generally not severe. However, if they persist or become bothersome, it is advisable to consult your healthcare provider.
In addition to these, some individuals have reported other side effects such as high blood sugar, joint pain, chest pain, muscle pain, wheezing, and acne. While these are less common, you should still be aware of them and seek guidance from a healthcare professional if they occur.
There are also rare but serious side effects that require immediate medical attention. These include signs of liver damage, such as persistent nausea or vomiting, loss of appetite, dark urine, stomach or abdominal pain, and yellowing of the skin or eyes. Severe allergic reactions, though rare, are also possible, with symptoms like rash, itching or swelling especially on the face, tongue, or throat, severe dizziness, and trouble breathing.
If you develop a rash, even though it is common and usually not serious, it is important to inform your doctor immediately as it could sometimes indicate a severe reaction. Always stay vigilant and report any unusual or severe symptoms to your healthcare provider promptly.
Kalydeco Interactions
What does the drug KALYDECO do?
KALYDECO (ivacaftor) is a medication used to treat cystic fibrosis in patients with specific mutations in the CFTR gene. It works by improving the function of the defective protein made by the CFTR gene, thereby enhancing chloride transport across cell membranes. This helps to improve lung function and reduce symptoms associated with cystic fibrosis.
Why is KALYDECO so expensive?
KALYDECO is expensive due to several factors, including the high cost of research and development, the complexity of manufacturing, and the relatively small patient population it serves. As a medication specifically designed to treat certain mutations of cystic fibrosis, it targets a niche market, which can lead to higher pricing to recoup the investment in its development. Additionally, the regulatory and approval processes for such specialized drugs can also contribute to the overall cost.
What is the difference between KALYDECO and Trikafta?
Kalydeco (ivacaftor) and Trikafta (elexacaftor/tezacaftor/ivacaftor) are both medications used to treat cystic fibrosis, but they differ in their composition and the specific mutations they target. Kalydeco is a CFTR potentiator that works by enhancing the function of the CFTR protein at the cell surface, and it is effective for patients with specific gating mutations. Trikafta, on the other hand, is a combination of three drugs: elexacaftor, tezacaftor, and ivacaftor. It is designed to treat a broader range of CFTR mutations, including the most common F508del mutation, by improving the processing and function of the CFTR protein.
How much does KALYDECO cost?
The cost of KALYDECO can vary significantly based on factors such as location, insurance coverage, and pharmacy pricing. Without insurance, the price can be quite high, often exceeding several hundred thousand dollars annually. It is advisable for individuals to consult with their healthcare provider or insurance company to get a more accurate estimate based on their specific circumstances. Additionally, there may be patient assistance programs available to help offset the cost.
What is unique about the cystic fibrosis drug KALYDECO?
KALYDECO (ivacaftor) is unique because it is one of the first medications designed to target the underlying cause of cystic fibrosis in patients with specific genetic mutations. It works by enhancing the function of the CFTR protein, which is defective in cystic fibrosis, thereby improving chloride transport across cell membranes. This can lead to improved lung function and other health benefits for patients with certain CFTR mutations.